Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Determination of Phase 3 Dose for X4P-001 in Patients with WHIM Syndrome

David C Dale, MD, Frank Caleb Firkin, MD, Audrey Anna Bolyard, RN, BS, Merideth L. Kelley, MSc, Emily Dick, BA, Sonja Hartmann, PhD, Karen Brown, PhD, Tarek M Ebrahim, MD, Kenneth J Gorelick, MD, Sudha Parasuraman, MD

Blood (2018) 132 (Supplement 1): 1102.

https://doi.org/10.1182/blood-2018-99-119840

Published: 2018

Journal Articles

X4P-001: A Novel Molecularly-Targeted Oral Therapy for Whim Syndrome

David Dale, MD, Audrey Anna Bolyard, RN, BS, Emily Dick, BA, Merideth L. Kelley, MS, Vahagn Makaryan, MD, Ramsey Johnson, MSM, Lu Gan, MD PhD, Sudha Parasuraman, MD

Blood (2017) 130 (Supplement 1): 995.

https://doi.org/10.1182/blood.V130.Suppl_1.995.995

Published: 2017

Journal Articles

Bortezomib In Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin Followed by Rituximab Maintenance In Patients with Relapsed or Refractory Follicular Lymphoma: Results of a Phase 2 Study.

Michael Craig, MD, Wahid T Hanna, MD, Fernando Cabanillas, MD, Chien-Shing Chen, MD, PhD, Sudha Parasuraman, MD, Rachel Neuwirth, MS, Owen A. O'Connor, MD, PhD

Blood (2010) 116 (21): 2798.

https://doi.org/10.1182/blood.V116.21.2798.2798

Published: 2010

Journal Articles

A Phase 3 Trial Comparing Bortezomib Plus Rituximab with Rituximab Alone In Patients with Relapsed, Rituximab-Naive or -Sensitive, Follicular Lymphoma

Bertrand Coiffier, MD, PhD, Evgenii Osmanov, MD, Xiaonan Hong, MD, Adriana Scheliga, MD, Jiri Mayer, MD, PhD, Fritz C Offner, MD, PhD, Simon A. Rule, MD, Adriana Teixeira, MD, Jan A Walewski, MD, PhD, DSc, Michael Crump, MD, FRCPC, Ofer Shpilberg, MD, MPH, Robert Hermann, MD, Sudha Parasuraman, MD, Eugene Zhu, PhD, Christopher Enny, BS, Panteli Theocharous, MSc, PhD, Helgi van de Velde, MD, PhD, Yusri Elsayed, MD, PhD, Pier Luigi Zinzani, MD, PhD

Blood (2010) 116 (21): 857.

https://doi.org/10.1182/blood.V116.21.857.857

Published: 2010

Journal Articles

Rapid Prospective Identification of Non-Germinal Center B Cell-Like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL) Patients for Targeted Trials: Early Results From PYRAMID, A Phase 2 Randomized Study of R-CHOP ± Bortezomib In Newly Diagnosed Non-GCB DLBCL.

Kevin Doner, MD, Ian W. Flinn, MD, PhD, Brian K. Ulrich, MD, Stephen J. Noga, MD, PhD, Naveed M. Chowhan, MD, Steven W. Papish, MD, Tallat Mahmood, MD, James A Reeves, MD, Nicholas J. Di Bella, MD, Gerald J. Robbins, MD, Radhakrishnan Ramchandren, MD, Sein Aung, MD, William Lawler, MD, Sudha Parasuraman, MD, Maria M. Corvez, BA, George Mulligan, PhD, John P. Leonard, MD

Blood (2010) 116 (21): 1792.

https://doi.org/10.1182/blood.V116.21.1792.1792

Published: 2010

NARROW

Determination of Phase 3 Dose for X4P-001 in Patients with WHIM Syndrome

X4P-001: A Novel Molecularly-Targeted Oral Therapy for Whim Syndrome

Bortezomib In Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin Followed by Rituximab Maintenance In Patients with Relapsed or Refractory Follicular Lymphoma: Results of a Phase 2 Study.

A Phase 3 Trial Comparing Bortezomib Plus Rituximab with Rituximab Alone In Patients with Relapsed, Rituximab-Naive or -Sensitive, Follicular Lymphoma

Rapid Prospective Identification of Non-Germinal Center B Cell-Like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL) Patients for Targeted Trials: Early Results From PYRAMID, A Phase 2 Randomized Study of R-CHOP ± Bortezomib In Newly Diagnosed Non-GCB DLBCL.

Email alerts

ASH Publications

American Society of Hematology

Determination of Phase 3 Dose for X4P-001 in Patients with WHIM Syndrome

X4P-001: A Novel Molecularly-Targeted Oral Therapy for Whim Syndrome

Bortezomib In Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin Followed by Rituximab Maintenance In Patients with Relapsed or Refractory Follicular Lymphoma: Results of a Phase 2 Study.

A Phase 3 Trial Comparing Bortezomib Plus Rituximab with Rituximab Alone In Patients with Relapsed, Rituximab-Naive or -Sensitive, Follicular Lymphoma

Rapid Prospective Identification of Non-Germinal Center B Cell-Like (GCB) Diffuse Large B-Cell Lymphoma (DLBCL) Patients for Targeted Trials: Early Results From PYRAMID, A Phase 2 Randomized Study of R-CHOP ± Bortezomib In Newly Diagnosed Non-GCB DLBCL.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only